Navigation Links
High Degree of Disease Prevalence Sustains Diabetes Diagnostics Market in Europe, Finds Frost & Sullivan
Date:11/28/2012

LONDON, Nov. 28, 2012 /PRNewswire/ -- The rising incidence of diabetes in Europe has presented the diagnostics market with significant growth opportunities. Diabetes organizations expect the patient pool in Europe to reach 64.2 million by 2030. This will increase testing volumes and thereby promote the need for diagnostic products and accessories across labs and hospitals.

New analysis from Frost & Sullivan (http://www.healthcare.frost.com), European Diabetes Diagnostics Market, finds that the market earned revenues of over $3.97 billion in 2011 and estimates this to reach $5.93 billion in 2018.

The proven efficacy of point-of-care testing (POCT) HbA1c and glucose tests has encouraged their adoption. In most European countries, these tests are a part of routine screening programmes.

"Doctors and diabetes specialists recommend HbA1C tests once every three months for type 1 and type 2 diabetes patients," says Frost & Sullivan Senior Research Analyst K. Srinivas Sashidhar. "Disease awareness programmes will further ensure regular monitoring of blood sugar levels."

However, low-cost suppliers are increasingly entering the market. This leads to stiff competition and intense pressure on established manufacturers to introduce innovative, automated and efficient monitors.

To achieve high profit margins, market participants must develop customised, result-oriented products. There is growing focus on self monitoring of blood glucose (SMBG), POCT HbA1C and glucose meters that can facilitate quicker measurements. Bundling these with other tests such as cholesterol monitoring is also essential.

"Non-invasive glucose meters with enhanced mobile connectivity and data management features in new systems are likely to dominate the market soon," notes Sashidhar. "Improved optical sensitivity and infra-red spectroscopy will improve work flow efficiencies."

Developing solutions with sufficient differentiation features is the key to staying competitive in this high-potential market.

If you are interested in more information on this research, please send an email to Anna Zanchi, Corporate Communications, at anna.zanchi@frost.com

European Diabetes Diagnostics Market is part of the Life Sciences Growth Partnership Services program, which also includes research in the following areas: Antihypertensive Market in Select SADC Countries, Opportunity Analysis for Biosimilars in South Korea, European Alzheimer's Disease Medication Market, and Contract Research and Manufacturing Services Market in India. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion
Join Us:           Join our community
Subscribe:       Newsletter on "the next big thing"
Register:         Gain access to visionary innovation

Contact
Anna Zanchi
Corporate Communications – Europe
P: +39.02.4851 6133
E: anna.zanchi@frost.com
http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. No Medical Degree Necessary: An Easy Guide to Understanding Your Probiotic Supplement Label
2. Berlin Packaging, Sanner USA Partner To Sell New Sanner 360 degree Desiccant Capsule In U.S.
3. Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS
4. iSALUS Healthcares chairman receives national honors from Samaritans Purse - an international organization providing spiritual and physical aid to victims of war, poverty, natural disaster and disease.
5. Research Published in European Journal of Pharmacology Shows that Star Scientifics Anatabine Suppresses Brain Inflammation in Animal Model of Alzheimers Disease and in Blood
6. Exercise Rate Related to Improvements in Parkinsons Disease
7. XBiotech Reports Positive Phase II Interim Analysis Results in Vascular Disease
8. Capital Digestive Care Leads the Way in the Fight to Unmask Reflux Disease During National GERD Awareness Week
9. Proteonomix, Inc. Announces Screening of Patients with End Stage Liver Disease in its Clinical Study of UMK-121
10. NeuroDerm Announces Enrollment in a Phase 1 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
11. Shire Leads New Initiative to Reveal Challenges Facing Rare Disease Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... and competitive market to drive long-term market growth ... very common set of chronic disorders that affect ... disparate in terms of their symptoms and key ... by dysregulation of immune pathways and an inappropriate ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
(Date:2/4/2016)... Feb. 4, 2016  Aethlon Medical, Inc. (Nasdaq: ... biofiltration devices to treat life-threatening diseases, today announced ... ended December 31, 2015. --> ... set forth in our last quarterly call, we ... our long-term objective to establish the Aethlon Hemopurifier® ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... ... US Sports Camps , official operators of Nike Yoga Camps, announces ... training. ChildLight Yoga Studio is centrally situated in the picturesque New England city of ... founder Lisa Flynn expresses her excitement, “We are thrilled to be partnering with US ...
(Date:2/5/2016)... Texas (PRWEB) , ... February 05, 2016 , ... ... to allow users to search for and donate to Give To Cure’s campaign that ... an app that lets users make and share payments through a smart device. In ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Justin Scott and Dr. ... Annual No Cost Dental Day to individuals in need. The event is scheduled to ... No Cost Dental Day is to provide dental care to community members in need. ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... In sleep, ... form as a dream. A hallmark feature of patients with eating disorders is significant ... The eating disorder behaviors and obsessions are regarded as maladaptive means for coping with ...
(Date:2/5/2016)... ... ... Calls Blacklist has just been updated by mobile app developer Vlad Lee. The ... known bugs within the app. Calls Blacklist allows its users to only have to ... their device’s battery power or memory. It provides a powerful call blocker that is ...
Breaking Medicine News(10 mins):